Clinical Trials Browser

Not yet recruiting × Triple Negative Breast Neoplasms × anlotinib × Clear all

NCT07139470 2025-08-24

Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer

Phase 1/2 Not yet recruiting

Triple Negative Breast Neoplasms